Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis
- PMID: 28304090
- PMCID: PMC5358515
- DOI: 10.1111/jgs.14668
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis
Abstract
Objectives: To evaluate the efficacy of treatment options to reduce osteoporotic fracture risk in men.
Design: Systematic review and meta-analysis.
Setting: Randomized clinical trials that evaluated the efficacy of a treatment for osteoporosis or low bone mineral density for adult men and reported fracture outcomes.
Participants: Men.
Measurements: PubMed, Embase, and the Cochrane Library databases were searched for relevant studies. Information was extracted from included studies on participant sociodemographic characteristics, number of male participants, treatment evaluated, comparator for evaluated treatment, study duration, and fracture outcomes. Risk of bias of individual studies was assessed using measures recommended by the Cochrane Collaboration.
Results: Twenty-four articles reporting results for 22 studies (including 4,868 male participants) met strict inclusion criteria. Fixed-effects meta-analyses using the Mantel-Haenszel method demonstrated significantly lower risk of vertebral fractures with alendronate (relative risk (RR) = 0.328, 95% confidence interval (CI) = 0.155-0.692) and risedronate (RR = 0.428, 95% CI = 0.245-0.746) but not with calcitonin (RR = 0.272, 95% CI = 0.046-1.608) or denosumab (RR = 0.256, 95% CI = 0.029-2.238) than in controls. For bisphosphonates as a treatment category, meta-analyses demonstrated significantly lower risk of vertebral fractures (RR = 0.368, 95% CI = 0.252-0.537) and nonvertebral fractures (RR = 0.604, 95% CI = 0.404-0.904) than in controls. The meta-analysis finding that bisphosphonates significantly reduce nonvertebral fracture risk was not robust to sensitivity analysis.
Conclusion: Bisphosphonates reduce the risk of vertebral and possibly nonvertebral fractures for men with osteoporosis. Further studies are needed to evaluate the efficacy of bisphosphonates for reducing nonvertebral fracture risk and the efficacy of nonbisphosphonates for reducing vertebral and nonvertebral fracture risk in men with osteoporosis.
Keywords: fractures; meta-analysis; osteoporosis; systematic review.
© 2016, Copyright the Authors Journal compilation © 2016, The American Geriatrics Society.
Conflict of interest statement
Conflict of Interest Statement: Dr. Greenspan is on the scientific advisory board for Merck & Co. Dr. Nayak has no conflicts of interest.
Figures
Similar articles
-
Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.Osteoporos Int. 2016 Nov;27(11):3289-3300. doi: 10.1007/s00198-016-3654-z. Epub 2016 Jun 7. Osteoporos Int. 2016. PMID: 27273112 Review.
-
Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.Menopause. 2015 Sep;22(9):1021-5. doi: 10.1097/GME.0000000000000466. Menopause. 2015. PMID: 25944523
-
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.Clin Invest Med. 2022 Sep 21;45(3):E14-22. doi: 10.25011/cim.v45i3.38875. Clin Invest Med. 2022. PMID: 36149052
-
Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2018 Jun 26;319(24):2532-2551. doi: 10.1001/jama.2018.6537. JAMA. 2018. PMID: 29946734 Review.
-
Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.Osteoporos Int. 2015 Sep;26(9):2355-63. doi: 10.1007/s00198-015-3148-4. Epub 2015 May 6. Osteoporos Int. 2015. PMID: 25944731
Cited by
-
Estrogen and estrogen receptors mediate the mechanobiology of bone disease and repair.Bone. 2024 Nov;188:117220. doi: 10.1016/j.bone.2024.117220. Epub 2024 Aug 5. Bone. 2024. PMID: 39106937 Review.
-
Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study.J Bone Miner Res. 2024 Sep 26;39(10):1424-1433. doi: 10.1093/jbmr/zjae090. J Bone Miner Res. 2024. PMID: 38861422 Free PMC article.
-
Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.Osteoporos Int. 2024 Aug;35(8):1377-1393. doi: 10.1007/s00198-024-07118-0. Epub 2024 May 11. Osteoporos Int. 2024. PMID: 38733394 Review.
-
A narrative review of the pharmaceutical management of osteoporosis.Ann Jt. 2023 Jun 20;8:25. doi: 10.21037/aoj-23-2. eCollection 2023. Ann Jt. 2023. PMID: 38529240 Free PMC article. Review.
-
Male Osteoporosis and Frailty.Indian J Orthop. 2023 Nov 1;57(Suppl 1):237-244. doi: 10.1007/s43465-023-01027-w. eCollection 2023 Dec. Indian J Orthop. 2023. PMID: 38107814 Review.
References
-
- U.S. Department of Health and Human Services. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004. Bone Health and Osteoporosis: A Report of the Surgeon General.
-
- Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007 Mar;22(3):465–475. - PubMed
-
- Bass E, French DD, Bradham DD, et al. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol. 2007 Jul;17(7):514–519. - PubMed
-
- Brenneman SK, Yurgin N, Fan Y. Cost and management of males with closed fractures. Osteoporos Int. 2013 Mar;24(3):825–833. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
